Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 2
1996 3
1997 3
1998 1
1999 1
2000 2
2005 1
2009 1
2012 3
2013 3
2014 2
2015 3
2016 2
2017 3
2019 3
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J. Collins DM, et al. Among authors: bossenmaier b. Clin Cancer Res. 2021 Feb 1;27(3):807-818. doi: 10.1158/1078-0432.CCR-20-2007. Epub 2020 Oct 29. Clin Cancer Res. 2021. PMID: 33122343 Free PMC article. Clinical Trial.
Acquired Resistance to Antibody-Drug Conjugates.
Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Collins DM, et al. Among authors: bossenmaier b. Cancers (Basel). 2019 Mar 20;11(3):394. doi: 10.3390/cancers11030394. Cancers (Basel). 2019. PMID: 30897808 Free PMC article. Review.
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
Sustmann C, Dickopf S, Regula JT, Kettenberger H, Mølhøj M, Gassner C, Weininger D, Fenn S, Manigold T, Kling L, Künkele KP, Schwaiger M, Bossenmaier B, Griese JJ, Hopfner KP, Graff-Meyer A, Stahlberg H, Ringler P, Lauer ME, Brinkmann U, Schaefer W, Klein C. Sustmann C, et al. Among authors: bossenmaier b. MAbs. 2019 Nov-Dec;11(8):1402-1414. doi: 10.1080/19420862.2019.1661736. Epub 2019 Sep 17. MAbs. 2019. PMID: 31526159 Free PMC article.
Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.
Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N, Elschenbroich S, Klammer M, Blackler A, Liao WL, Tian Y, Friess T, Bossenmaier B, Dietmann G, Schaab C, Hembrough T, Ceppi M. Ducret A, et al. Among authors: bossenmaier b. PLoS One. 2019 Mar 21;14(3):e0213892. doi: 10.1371/journal.pone.0213892. eCollection 2019. PLoS One. 2019. PMID: 30897176 Free PMC article. Clinical Trial.
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G. Bauss F, et al. Among authors: bossenmaier b. Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14. Mol Oncol. 2016. PMID: 27507537 Free PMC article.
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, Bossenmaier B, Niederfellner G, Tai CH, Reiter Y, Pastan I. Leshem Y, et al. Among authors: bossenmaier b. Cancer Immunol Res. 2017 Aug;5(8):685-694. doi: 10.1158/2326-6066.CIR-16-0330. Epub 2017 Jul 3. Cancer Immunol Res. 2017. PMID: 28674083 Free PMC article.
Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation.
van Dieck J, Schmid V, Heindl D, Dziadek S, Schraeml M, Gerg M, Massoner P, Engel AM, Tiefenthaler G, Vural S, Stritt S, Tetzlaff F, Soukupova M, Kopetzki E, Bossenmaier B, Thomas M, Klein C, Mertens A, Heller A, Tacke M. van Dieck J, et al. Among authors: bossenmaier b. Chem Biol. 2014 Mar 20;21(3):357-68. doi: 10.1016/j.chembiol.2013.12.018. Epub 2014 Feb 13. Chem Biol. 2014. PMID: 24529991
34 results